Seed Therapeutics

Name

Seed Therapeutics

Legal name

SEED Therapeutics, Inc.

Website

https://seedtherapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Targeted Protein Degradation Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Molecular glue degraders
• Targeted protein degradation
• Clinical-stage biotechnology
• Cancer therapeutics
• Ubiquitin-proteasome system

Headquarters

HQ city

King Of Prussia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Partnership Payments and Milestones: SEED receives upfront payments, preclinical, clinical, regulatory, and sales milestone payments from pharmaceutical partners, plus tiered royalties on net sales of commercialized products. Eli Lilly partnership: up to ~$780 million in milestones. Eisai partnership: up to $1.5 billion in milestones plus royalties.
2. Equity Financing: The company has raised approximately $60 million through equity financing and partnership payments from Eli Lilly and Eisai, including a $30 million Series A-3 financing completed in 2025.
3. Future Product Sales: Post-approval, revenue will be generated through sales of molecular glue degrader therapeutics, with potential for both direct commercialization and distribution through pharmaceutical partners.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Seed Therapeutics is a clinical-stage biotechnology company developing rationally designed molecular glue degraders that harness the ubiquitin-proteasome system to eliminate disease-causing proteins previously considered undruggable. Its lead candidate ST-01156 is an oral brain-penetrant RBM39 degrader currently in Phase 1 clinical trials for advanced solid tumors, with additional pipeline programs in neurodegeneration (Tau degrader), immunology, and virology developed through strategic partnerships with Eli Lilly and Eisai.

Product overview

Seed Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by historically undruggable proteins. The company's proprietary RITE3™ platform enables targeted protein degradation with small-molecule precision by systematically identifying optimal E3 ligase-target pairs. The company's lead clinical candidate is ST-01156, an oral RBM39 degrader currently in Phase 1 trials for multiple RBM39-dependent cancers including Ewing sarcoma, hepatocellular carcinoma, KRAS-mutant cancers, and neuroblastoma. The pipeline also includes a Tau degrader program for Alzheimer's disease (in preclinical development), as well as multiple partnered programs in immunology and virology developed in collaboration with Eli Lilly and Eisai. The company has nine molecular glue programs spanning oncology, neurodegeneration, immunology, and virology.

Differentiator

Problem solved

Functional benefit

Products and services

• ST-01156 (RBM39 Degrader) An orally administered, brain-penetrant molecular glue degrader that selectively degrades RBM39, a key regulator of RNA splicing and transcription required for survival in several cancer types. Currently in Phase 1 clinical trials for advanced solid tumors with focus on RBM39-dependent cancers including Ewing sarcoma, hepatocellular carcinoma, KRAS-mutant cancers, and neuroblastoma. FDA Orphan Drug and Rare Pediatric Disease Designations granted for Ewing sarcoma.
• Tau Degrader Program A molecular glue degrader program targeting Tau protein for Alzheimer's disease and neurodegenerative indications. Currently in lead identification stage with in vivo PK completed in 2H 2025 and IND filing targeted for 2026. Developed in partnership with Eli Lilly and Eisai.

Quantifiable outcome

• Complete tumor regression achieved in preclinical xenograft models of Ewing sarcoma, neuroblastoma, and KRAS-mutant colon cancer
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor and core.

• University of PennsylvaniaminorStrategic or Co-development Partner · 27 April 2025Research collaboration with Dr. Luca Busino's laboratory on dual PROTAC synergy using two E3 ligases (VHL and KEAP1) to overcome the hook effect and enhance KRAS G12D degradation. SEED provided funding support for this research.
• Eisai Co., Ltd.coreStrategic or Co-development Partner · 6 August 2024Strategic research collaboration to discover and develop novel molecular glue degraders for neurodegeneration and oncology indications. SEED entitled to receive upfront and milestone payments of up to $1.5 billion plus tiered royalties. Eisai led the $24 million first close of Series A-3 financing and joined as strategic investor and collaborator in August 2024.
• Eli Lilly and CompanycoreStrategic or Co-development Partner · 13 November 2020Research collaboration and license agreement for discovery and development of molecular glue degraders. SEED received $10 million upfront cash and $10 million equity investment. SEED eligible for up to approximately $780 million in potential preclinical, clinical, regulatory, and commercial milestones, plus tiered royalties on net sales. Lilly has been a cornerstone investor and collaborator since SEED's inception.
• BeyondSpring Inc.coreOthersSEED Therapeutics is a subsidiary of BeyondSpring Inc. (NASDAQ: BYSI). BeyondSpring is an early incubator and investor in SEED's TPD technology. Dr. Lan Huang serves as CEO and Chairman of both companies.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders to treat cancer and other diseases. Closely comparable to SEED in modality (rationally designed molecular glues), therapeutic-area focus, and pipeline-stage maturity.
• Arvinas: Pioneer in targeted protein degradation using PROTAC degraders, with multiple clinical-stage oncology programs. Direct competitor in the TPD modality with a more clinically advanced pipeline and big-pharma partnerships.
• Kymera Therapeutics: Clinical-stage biotech developing heterobifunctional degraders and molecular glues across oncology and immunology. Comparable as a platform-based TPD company with big-pharma partnerships and multiple clinical assets.
• C4 Therapeutics: Clinical-stage company developing small-molecule degraders (TORPEDO platform) for cancer and neurodegenerative diseases. Directly comparable in TPD modality and in targeting oncology plus neurodegeneration.
• Nurix Therapeutics: Clinical-stage TPD company with both targeted protein degraders and 'inverse' ligase modulators for oncology and immunology. Comparable in platform-based degrader approach and pharma partnerships (Sanofi, Gilead).

Emerging players

• Foghorn Therapeutics: Clinical-stage biotech developing medicines targeting the chromatin regulatory system, with a protein degradation component. Adjacent competitor in oncology focused on dysregulated gene expression.
• Recursion Pharmaceuticals: AI-enabled biotech applying machine learning to drug discovery, including partnerships in protein degradation and oncology. Comparable as a technology-driven, platform-based drug discovery company, though with a broader therapeutic remit.

Broad incumbents

• Bristol Myers Squibb: Large oncology company with the CELMoD molecular glue platform (e.g., iberdomide, mezigdomide) derived from its Celgene acquisition. Represents a broad incumbent pursuing the same molecular glue modality at scale, and a potential acquirer of SEED.
• Amgen: Large biopharma with active investments in protein degradation, including the acquisition of TPD players (e.g., Nuevolution). Relevant comparable as both a potential partner/acquirer and a competitor pursuing the same therapeutic modality.

Others

• Eli Lilly and Company: Cornerstone strategic investor and research collaborator of SEED since inception, with up to ~$780M in milestones. While primarily a partner rather than competitor, Lilly also runs internal TPD programs and is therefore a relevant comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/seedtx
• LinkedInlinkedin.com/company/seed-therapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seed Therapeutics